Subscribe now
23andMe's breast cancer test may create false sense of security

23andMe's breast cancer test may create false sense of security

7 March 2018

Genomics firm 23andMe is the first to receive approval for direct-to-consumer cancer gene tests in the US, but will recipients misunderstand the results?
Pipette over small vials of blue liquid

Should cash-strapped NHS pay for unproven gene sequencing?

5 July 2017

The UK wants to make genomics a central part of healthcare, but we don't yet know enough about our genes to be sure it will bring benefits

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Sign up
Piano Exit Overlay Banner Mobile Piano Exit Overlay Banner Desktop